@article{ff28eff449ad4554b7b8382ea2176d8a,
title = "FBXL4 suppresses mitophagy by restricting the accumulation of NIX and BNIP3 mitophagy receptors",
abstract = "To maintain both mitochondrial quality and quantity, cells selectively remove damaged or excessive mitochondria through mitophagy, which is a specialised form of autophagy. Mitophagy is induced in response to diverse conditions, including hypoxia, cellular differentiation and mitochondrial damage. However, the mechanisms that govern the removal of specific dysfunctional mitochondria under steady-state conditions to fine-tune mitochondrial content are not well understood. Here, we report that SCFFBXL4, an SKP1/CUL1/F-box protein ubiquitin ligase complex, localises to the mitochondrial outer membrane in unstressed cells and mediates the constitutive ubiquitylation and degradation of the mitophagy receptors NIX and BNIP3 to suppress basal levels of mitophagy. We demonstrate that the pathogenic variants of FBXL4 that cause encephalopathic mtDNA depletion syndrome (MTDPS13) do not efficiently interact with the core SCF ubiquitin ligase machinery or mediate the degradation of NIX and BNIP3. Thus, we reveal a molecular mechanism whereby FBXL4 actively suppresses mitophagy by preventing NIX and BNIP3 accumulation. We propose that the dysregulation of NIX and BNIP3 turnover causes excessive basal mitophagy in FBXL4-associated mtDNA depletion syndrome.",
keywords = "BNIP3, FBXL4, mitochondria, mitophagy, NIX/BNIP3L",
author = "Nguyen-Dien, \{Giang Thanh\} and Kozul, \{Keri Lyn\} and Yi Cui and Brendan Townsend and Kulkarni, \{Prajakta Gosavi\} and Ooi, \{Soo Siang\} and Antonio Marzio and Nissa Carrodus and Steven Zuryn and Michele Pagano and Parton, \{Robert G.\} and Michael Lazarou and Millard, \{S. Sean\} and Taylor, \{Robert W.\} and Collins, \{Brett M.\} and Jones, \{Mathew J.K.\} and Pagan, \{Julia K.\}",
note = "Funding Information: We thank Rowan Tweedale, Stefan Thor and Uli Siebeck for critical reading and comments on the manuscript. We thank X. Qi for technical assistance. Imaging was performed at the Microscopy and Image Analysis Facility in the School of Biomedical Sciences at the University of Queensland. Lentiviruses were produced by the University of Queensland (UQ)‐Viral Vector Core. This work was supported by an Australian National Health and Medical Research Council (APP1183915 and APP1136021), Brain Foundation Research grant (2020), a Mito Foundation Incubator Grant (2022) and an Australian Research Council Future Fellowship (FT180100172) to J.K.P.; National Health and Medical Research Council of Australia grants (APP1140064 and APP1150083 and fellowship APP1156489) to R.G.P.; an Australian Research Council Discovery Project (DP210102704) to M.J.K.J.; AIRC/Marie Curie, American‐Italian Cancer Foundation (AICF) and NIH/T32CA009161 grants to A.M. This work was supported by the National Health and Medical Research Council (GNT1106471) and Australian Research Council (ARC) Discovery Project (DP200100347) to M.L. K.S. was supported by a Mito Foundation student scholarship. R.G.P. was supported by an NHMRC fellowship APP1156489 and is now an Australian Research Council (ARC) Laureate Fellow. R.W.T. is funded by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Medical Research Council International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Medical Research Council (MR/W019027/1), the Lily Foundation, Mito Foundation, the Pathological Society, the UK NIHR Biomedical Research Centre for Ageing and Age‐related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust and the UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of Adults and Children. B.M.C. is supported by an NHMRC Investigator Grant (APP2016410). S.Z. is supported by a Stafford Fox Foundation Fellowship. We also acknowledge and thank Milot Mirdita, Sergey Ovchinnikov, Martin Steinegger and the ColabFold team for making their AlphaFold2 modelling pipeline available for public use. Open access publishing facilitated by The University of Queensland, as part of the Wiley ‐ The University of Queensland agreement via the Council of Australian University Librarians. Funding Information: M.P. is a scientific cofounder of SEED Therapeutics; receives research funding from and is a shareholder in Kymera Therapeutics; and is a consultant for, a member of the scientific advisory board of, and has financial interests in CullGen, SEED Therapeutics, Triana Biomedicines, and Umbra Therapeutics. However, no research funds were received from these entities, and the findings presented in this manuscript were not discussed with any person in these companies. The other authors have no competing interests to declare. Publisher Copyright: {\textcopyright} 2023 The Authors. Published under the terms of the CC BY 4.0 license.",
year = "2023",
doi = "10.15252/embj.2022112767",
language = "English",
volume = "42",
journal = "The EMBO Journal",
issn = "0261-4189",
publisher = "EMBO Press",
}